Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics
Acta Pharmaceutica Sinica B
; (6): 3252-3276, 2023.
Article
in En
| WPRIM
| ID: wpr-1011121
Responsible library:
WPRO
ABSTRACT
Chemotherapy has occupied the critical position in cancer therapy, especially towards the post-operative, advanced, recurrent, and metastatic tumors. Paclitaxel (PTX)-based formulations have been widely used in clinical practice, while the therapeutic effect is far from satisfied due to off-target toxicity and drug resistance. The caseless multi-components make the preparation technology complicated and aggravate the concerns with the excipients-associated toxicity. The self-assembled PTX nanoparticles possess a high drug content and could incorporate various functional molecules for enhancing the therapeutic index. In this work, we summarize the self-assembly strategy for diverse nanodrugs of PTX. Then, the advancement of nanodrugs for tumor therapy, especially emphasis on mono-chemotherapy, combinational therapy, and theranostics, have been outlined. Finally, the challenges and potential improvements have been briefly spotlighted.
Full text:
1
Index:
WPRIM
Language:
En
Journal:
Acta Pharmaceutica Sinica B
Year:
2023
Type:
Article